Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation

Aggregation of α‐synuclein, an abundant and conserved pre‐synaptic brain protein, is implicated as a critical factor in several neurodegenerative diseases. These diseases, known as synucleinopathies, include Parkinson’s disease, dementia with Lewy bodies (LBs), diffuse LB disease, the LB variant of Alzheimer’s disease, multiple system atrophy, and neurodegeneration with brain iron accumulation type I. Although the precise nature of in vivoα‐synuclein function remains elusive, considerable knowledge has been accumulated about its structural properties and conformational behavior. α‐Synuclein is a typical natively unfolded protein. It is characterized by the lack of rigid, well‐defined, 3‐D structure and possesses remarkable conformational plasticity. The structure of this protein depends dramatically on its environment and it accommodates a number of unrelated conformations. This paper provides an overview of the biochemistry, biophysics, and neuropathology of α‐synuclein aggregation.

[1]  V. Uversky,et al.  Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.

[2]  Min Zhu,et al.  Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.

[3]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[4]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[5]  V. Uversky,et al.  Methionine oxidation, a-synuclein and Parkinson's disease , 2005 .

[6]  V. Uversky,et al.  Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. , 2002, Biochemistry.

[7]  D. Selkoe,et al.  Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[8]  V. Uversky,et al.  Methionine oxidation inhibits fibrillation of human α‐synuclein in vitro , 2002 .

[9]  S. Hammond,et al.  Phospholipase D Stimulates Release of Nascent Secretory Vesicles from the trans-Golgi Network , 1997, The Journal of cell biology.

[10]  Andrzej Galat,et al.  Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity--targets--functions. , 2003, Current topics in medicinal chemistry.

[11]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[12]  V. Uversky Intrinsically Disordered Proteins , 2000 .

[13]  Ewan W Blanch,et al.  A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins. , 2002, European journal of biochemistry.

[14]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[15]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[16]  V. Uversky,et al.  Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. , 2003, Biochemistry.

[17]  M. Goedert,et al.  The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy , 2000 .

[18]  C. Hertzman,et al.  A case‐control study of Parkinson's disease in a horticultural region of British Columbia , 1994, Movement disorders : official journal of the Movement Disorder Society.

[19]  V. Uversky,et al.  Role of individual methionines in the fibrillation of methionine-oxidized α-synuclein , 2004 .

[20]  W. Honer,et al.  Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. , 1998, The American journal of pathology.

[21]  L. Iakoucheva,et al.  Intrinsic Disorder and Protein Function , 2002 .

[22]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[23]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[25]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Lansbury,et al.  The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.

[27]  V. Uversky,et al.  Trimethylamine-N-oxide-induced folding of alpha-synuclein. , 2001, FEBS letters.

[28]  W. Spooren,et al.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. , 2002, EMBO reports.

[29]  Ikuko Fujiwara,et al.  Microscopic analysis of polymerization dynamics with individual actin filaments , 2002, Nature Cell Biology.

[30]  V. Uversky,et al.  Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.

[31]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[32]  V. Uversky,et al.  Trimethylamine‐N‐oxide‐induced folding of α‐synuclein , 2001 .

[33]  O. Axelson,et al.  Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.

[34]  M. Vila,et al.  Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.

[35]  S. Paik,et al.  Metal-Catalyzed Oxidation of α-Synuclein in the Presence of Copper(II) and Hydrogen Peroxide , 2000 .

[36]  C. Tanner,et al.  Environmental factors and Parkinson's disease , 1989, Neurology.

[37]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[38]  John Q. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[39]  Theodore W Randolph,et al.  Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. , 2003, Biochemistry.

[40]  T. Nagatsu [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.

[41]  M. Goedert Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[42]  Langston Jw,et al.  Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .

[43]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[44]  R. Crowther,et al.  Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. , 2000, Neuroscience letters.

[45]  Y. Lyubchenko,et al.  Effects of nitration on the structure and aggregation of α-synuclein , 2005 .

[46]  H. Dyson,et al.  Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. , 1999, Journal of molecular biology.

[47]  A. Minton Implications of macromolecular crowding for protein assembly. , 2000, Current opinion in structural biology.

[48]  K. Jellinger,et al.  Neuropathological spectrum of synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.

[49]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[50]  Y. Lyubchenko,et al.  Effects of nitration on the structure and aggregation of alpha-synuclein. , 2005, Brain research. Molecular brain research.

[51]  D. Ferrington,et al.  Repair of oxidized calmodulin by methionine sulfoxide reductase restores ability to activate the plasma membrane Ca-ATPase. , 1999, Biochemistry.

[52]  P. Jensen,et al.  Pathogenic effects of alpha-synuclein aggregation. , 2005, Brain research. Molecular brain research.

[53]  Marc S. Cortese,et al.  Flexible nets , 2005, The FEBS journal.

[54]  Kurt Jellinger,et al.  Amygdala pathology in Parkinson's disease , 2004, Acta Neuropathologica.

[55]  Ad Bax,et al.  Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.

[56]  M. Bennett The role of α-synuclein in neurodegenerative diseases , 2005 .

[57]  K. Prasad,et al.  Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells , 2000, Brain Research.

[58]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[59]  Christopher J. Oldfield,et al.  Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling , 2005, Journal of molecular recognition : JMR.

[60]  G. Pielak,et al.  Macromolecular crowding in the Escherichia coli periplasm maintains alpha-synuclein disorder. , 2006, Journal of molecular biology.

[61]  M. Bennett The role of alpha-synuclein in neurodegenerative diseases. , 2005, Pharmacology & therapeutics.

[62]  L. Lipkin,et al.  DIFFUSE INTRACYTOPLASMIC GANGLIONIC INCLUSIONS (LEWY TYPE) ASSOCIATED WITH PROGRESSIVE DEMENTIA AND QUADRIPARESIS IN FLEXION , 1961, Journal of neuropathology and experimental neurology.

[63]  J. Trojanowski,et al.  Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.

[64]  S. Zimmerman,et al.  Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. , 1991, Journal of molecular biology.

[65]  P. Lansbury,et al.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.

[66]  R. Anthony Crowther,et al.  Synthetic filaments assembled from C‐terminally truncated α‐synuclein , 1998 .

[67]  M. Cookson Hero versus antihero: The multiple roles of α-synuclein in neurodegeneration , 2006, Experimental Neurology.

[68]  M. Spillantini,et al.  Alpha‐synuclein dysfunction in Lewy body diseases , 2005, Movement disorders : official journal of the Movement Disorder Society.

[69]  D. Marsh,et al.  Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. , 2003, Biochemistry.

[70]  N. Wood,et al.  Molecular pathogenesis of Parkinson's disease. , 2005, Human molecular genetics.

[71]  A Keith Dunker,et al.  Natively Disordered Proteins , 2004, Applied bioinformatics.

[72]  Kiowa S. Bower,et al.  Accelerated α‐synuclein fibrillation in crowded milieu , 2002 .

[73]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[74]  V. Uversky,et al.  Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. , 2004, Biochemistry.

[75]  A. Singleton,et al.  Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. , 2004, Brain : a journal of neurology.

[76]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[77]  Thomas C. Südhof,et al.  α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.

[78]  Paul H. Axelsen,et al.  The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.

[79]  Vladimir N Uversky,et al.  What does it mean to be natively unfolded? , 2002, European journal of biochemistry.

[80]  S. Tsuji,et al.  Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. , 1998, Neuroscience letters.

[81]  P. Blumbergs,et al.  Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.

[82]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[83]  W. Gong,et al.  The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. , 2000, Immunopharmacology.

[84]  J. Trojanowski,et al.  Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses , 2003, Annals of the New York Academy of Sciences.

[85]  J. Trojanowski,et al.  Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[86]  Leonard Petrucelli,et al.  Molecular pathogenesis of Parkinson disease. , 2005, Archives of neurology.

[87]  Jeff Kuret,et al.  Rapid Anionic Micelle-mediated α-Synuclein Fibrillization in Vitro* , 2003, Journal of Biological Chemistry.

[88]  N. Voelcker,et al.  Annular α‐synuclein species from purified multiple system atrophy inclusions , 2004 .

[89]  S. Bottomley,et al.  Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[90]  T. Iwatsubo,et al.  Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila , 2003, Neuroscience Letters.

[91]  R. Edwards,et al.  Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[92]  H. Vorum,et al.  Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.

[93]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[94]  P J McLean,et al.  Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. , 2000, The Journal of biological chemistry.

[95]  P. Romero,et al.  Sequence complexity of disordered protein , 2001, Proteins.

[96]  H. Braak,et al.  Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry , 1999, Neuroscience Letters.

[97]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[98]  V. Uversky,et al.  Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. , 2004, Chemistry & biology.

[99]  Jeff Kuret,et al.  Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. , 2003, The Journal of biological chemistry.

[100]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[101]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[102]  E. Stadtman,et al.  Methionine residues as endogenous antioxidants in proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[103]  S. Scarlata,et al.  Membrane binding and self-association of alpha-synucleins. , 2001, Biochemistry.

[104]  F. Kamp,et al.  Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.

[105]  Christopher J. Oldfield,et al.  Intrinsically disordered protein. , 2001, Journal of molecular graphics & modelling.

[106]  P. Romero,et al.  Natively Disordered Proteins , 2008, Applied bioinformatics.

[107]  N. Voelcker,et al.  Annular alpha-synuclein species from purified multiple system atrophy inclusions. , 2004, Journal of neurochemistry.

[108]  P. Lansbury,et al.  Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. , 2000, Annals of the New York Academy of Sciences.

[109]  P. Lansbury,et al.  Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.

[110]  R. Ellis Macromolecular crowding : obvious but underappreciated , 2022 .

[111]  V. Uversky,et al.  Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.

[112]  R. Nussbaum,et al.  Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein* , 2002, The Journal of Biological Chemistry.

[113]  G. Johnson,et al.  Transglutaminase Cross‐Linking of the τ Protein , 1995 .

[114]  Mark R Cookson,et al.  The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.

[115]  W. Woods,et al.  A Novel Mechanism of Interaction between α-Synuclein and Biological Membranes , 2006 .

[116]  D. Selkoe,et al.  Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. , 2003, The Journal of biological chemistry.

[117]  M. L. Schmidt,et al.  Pathobiology of the Lewy body. , 1999, Advances in neurology.

[118]  N. Wood,et al.  Expanding insights of mitochondrial dysfunction in Parkinson's disease , 2006, Nature Reviews Neuroscience.

[119]  N. Bonini,et al.  Snaring the Function of α-Synuclein , 2005, Cell.

[120]  J Q Trojanowski,et al.  Synucleinopathies: clinical and pathological implications. , 2001, Archives of neurology.

[121]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[122]  V. Uversky,et al.  Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates Fibrils , 2004 .

[123]  Vladimir N Uversky,et al.  Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. , 2002, Neurotoxicology.

[124]  A. Goldberg,et al.  PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.

[125]  E. Masliah,et al.  Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. , 1995, Biochemistry.

[126]  Vladimir N Uversky,et al.  A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders , 2003, Journal of biomolecular structure & dynamics.

[127]  V. Uversky,et al.  The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.

[128]  A. Fink Natively unfolded proteins. , 2005, Current opinion in structural biology.

[129]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[130]  Michel Goedert,et al.  Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.

[131]  T. Iwatsubo,et al.  Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .

[132]  P Falkai,et al.  Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. , 1999, Neuroscience letters.

[133]  D. Heber,et al.  Baicalin is a major component of PC‐SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest , 2001, The Prostate.

[134]  D. A. Monte The role of environmental agents in Parkinson's disease , 2001, Clinical Neuroscience Research.

[135]  Christopher G. Adda,et al.  Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. , 2004, Journal of molecular biology.

[136]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[137]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[138]  V. Uversky,et al.  Why are “natively unfolded” proteins unstructured under physiologic conditions? , 2000, Proteins.

[139]  G. Irvine,et al.  Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. , 2000, European journal of biochemistry.

[140]  H. Kato,et al.  Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. , 2006, Biochemistry.

[141]  Gary J. Pielak,et al.  Macromolecular Crowding in the Escherichia coli Periplasm Maintains α-Synuclein Disorder , 2006 .

[142]  Soo-Youl Kim,et al.  Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[143]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[144]  A. Manning-Boğ,et al.  Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.

[145]  H. Federoff,et al.  Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? , 2005, Brain research. Molecular brain research.

[146]  V. Uversky,et al.  Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. , 2003, Protein science : a publication of the Protein Society.

[147]  Charles N. Serhan,et al.  Altered Fatty Acid Composition of Dopaminergic Neurons Expressing α-Synuclein and Human Brains with α-Synucleinopathies* , 2003, Journal of Biological Chemistry.

[148]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[149]  E. Masliah,et al.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.

[150]  V. Uversky,et al.  Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers , 2003 .

[151]  P. Auluck,et al.  Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.

[152]  D. Dickson,et al.  Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease , 1991, Neurology.

[153]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[154]  Shigeo Hirai,et al.  NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy , 1998, Acta Neuropathologica.

[155]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[156]  V. Uversky,et al.  Certain Metals Trigger Fibrillation of Methionine-oxidized α-Synuclein* , 2003, Journal of Biological Chemistry.

[157]  R. Casadio,et al.  Effect of molecular confinement on internal enzyme dynamics: frequency domain fluorometry and molecular dynamics simulation studies. , 2002, Biopolymers.

[158]  K. Wakabayashi,et al.  A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy , 2004, Neuropathology and applied neurobiology.

[159]  G J Pielak,et al.  Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. , 2001, Protein science : a publication of the Protein Society.

[160]  A. Young,et al.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[161]  Zoran Obradovic,et al.  The protein trinity—linking function and disorder , 2001, Nature Biotechnology.

[162]  P. Tompa The interplay between structure and function in intrinsically unstructured proteins , 2005, FEBS letters.

[163]  K. Herholz,et al.  Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure , 1999, Journal of Neurology.

[164]  Y. Agid,et al.  Clinical and pathological features in hydrocarbon‐induced Parkinsonism , 1996, Annals of neurology.

[165]  H. Ischiropoulos,et al.  Biological selectivity and functional aspects of protein tyrosine nitration. , 2003, Biochemical and biophysical research communications.

[166]  D. D. Di Monte The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.

[167]  David W. Miller,et al.  α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication , 2004, Neurology.

[168]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[169]  G. Irvine,et al.  Identification of the region of non‐Aβ component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity , 2001, Journal of neurochemistry.

[170]  Vladimir N. Uversky,et al.  Forcing Nonamyloidogenic β-Synuclein To Fibrillate† , 2005 .

[171]  G. Irvine,et al.  The N‐terminal region of non‐Aβ component of Alzheimer's Disease amyloid is responsible for its tendency to assume β‐sheet and aggregate to form fibrils , 1998 .

[172]  E. Masliah,et al.  C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders , 2000, Acta Neuropathologica.

[173]  P. Højrup,et al.  &agr;-Synuclein filaments bind the transcriptional regulator HMGB-1 , 2004, Neuroreport.

[174]  Donato A Di Monte,et al.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.

[175]  R. Ferrante,et al.  Tissue Transglutaminase Is Increased in Huntington's Disease Brain , 1999, Journal of neurochemistry.

[176]  S. Lindquist,et al.  Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.

[177]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[178]  E. Altschuler,et al.  Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. , 1999, Medical hypotheses.

[179]  Christopher G. Adda,et al.  Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity , 2004 .

[180]  P. Fraser,et al.  α‐Synuclein–synaptosomal membrane interactions , 2004 .

[181]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[182]  Takeshi Iwatsubo,et al.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.

[183]  Peter Tompa,et al.  The role of structural disorder in the function of RNA and protein chaperones , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[184]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[185]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[186]  A. Singleton,et al.  Association between cardiac denervation and parkinsonism caused by α‐synuclein gene triplication , 2004 .

[187]  N. Copeland,et al.  Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[188]  B. Festoff,et al.  Cross-linking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. , 1994, FEBS letters.

[189]  P. S. St George-Hyslop,et al.  α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.

[190]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[191]  F. Kamp,et al.  Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. , 2006, The Journal of biological chemistry.

[192]  R. Perrin,et al.  Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.

[193]  B. Festoff,et al.  Cross‐linking of β‐amyloid protein precursor catalysed by tissue transglutaminase , 1994 .

[194]  J. Langston,et al.  Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.

[195]  Z. Obradovic,et al.  Identification and functions of usefully disordered proteins. , 2002, Advances in protein chemistry.

[196]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[197]  L. Meijer,et al.  Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.

[198]  V. Uversky,et al.  Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. , 2005, Glycobiology.

[199]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[200]  W. Vogt Oxidation of methionyl residues in proteins: tools, targets, and reversal. , 1995, Free radical biology & medicine.

[201]  I. McKeith,et al.  Pathophysiology of synuclein aggregation in Lewy body disease , 2006, Mechanisms of Ageing and Development.

[202]  S. Furesz Chemical and biological properties of rifampicin. , 1970, Antibiotica et chemotherapia. Fortschritte. Advances. Progres.

[203]  M. Farrer,et al.  Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. , 2000, Journal of neurochemistry.

[204]  V. Uversky,et al.  Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations* , 2001, The Journal of Biological Chemistry.

[205]  M. Raftery,et al.  αB-Crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy , 2009, Neurotoxicity Research.

[206]  D. Housman,et al.  New Directions for Neurodegenerative Disease Therapy: Using Chemical Compounds to Boost the Formation of Mutant Protein Inclusions , 2006, Cell cycle.

[207]  Leonidas Stefanis,et al.  α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis , 2006, The Journal of Neuroscience.

[208]  L. Golbe Alpha-synuclein and Parkinson's disease. , 2003, Advances in neurology.

[209]  Susan Lindquist,et al.  Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.

[210]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[211]  Ji An Wu,et al.  Anti-HIV activity of medicinal herbs: usage and potential development. , 2001, The American journal of Chinese medicine.

[212]  P. Blumbergs,et al.  Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.

[213]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[214]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[215]  A Keith Dunker,et al.  Intrinsic disorder and protein function. , 2002, Biochemistry.

[216]  P. Radivojac,et al.  PROTEINS: Structure, Function, and Bioinformatics Suppl 7:176–182 (2005) Exploiting Heterogeneous Sequence Properties Improves Prediction of Protein Disorder , 2022 .

[217]  Jie Li,et al.  The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.

[218]  Peter L. Lantos,et al.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.

[219]  J Kim,et al.  Copper(II)-induced self-oligomerization of alpha-synuclein. , 1999, The Biochemical journal.

[220]  J. Trojanowski,et al.  Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.

[221]  F. Forastiere,et al.  Evaluation of risk of Parkinson's disease in a cohort of licensed pesticide users , 2002, Neurological Sciences.

[222]  M Yasui,et al.  Calcium, magnesium and aluminum concentrations in Parkinson's disease. , 1992, Neurotoxicology.

[223]  C. Goetz,et al.  A pure parkinsonian syndrome following acute carbon monoxide intoxication. , 1982, Archives of neurology.

[224]  M. Frasier,et al.  Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.

[225]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[226]  R. Kisilevsky Review: amyloidogenesis-unquestioned answers and unanswered questions. , 2000, Journal of structural biology.

[227]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[228]  V. Uversky,et al.  Role of Protein−Water Interactions and Electrostatics in α-Synuclein Fibril Formation† , 2004 .

[229]  Robert L Nussbaum,et al.  Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. , 2005, Biochemistry.

[230]  P. Tompa,et al.  Structural disorder throws new light on moonlighting. , 2005, Trends in biochemical sciences.

[231]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[232]  A. Lang,et al.  Interface between tauopathies and synucleinopathies: A tale of two proteins , 2006, Annals of neurology.

[233]  A. Fulton,et al.  How crowded is the cytoplasm? , 1982, Cell.

[234]  H. Ischiropoulos Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. , 1998, Archives of biochemistry and biophysics.

[235]  G. Johnson,et al.  Transglutaminase cross-linking of the tau protein. , 1995, Journal of neurochemistry.

[236]  A. Morris,et al.  Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.

[237]  K. Beyer α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers , 2006, Acta Neuropathologica.

[238]  J. Adair,et al.  Parkinsonism from methanol poisoning: Benefit from treatment with anti‐parkinson drugs , 1999, Movement disorders : official journal of the Movement Disorder Society.

[239]  C. Hogstedt,et al.  Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury--a case-referent study. , 1981, Scandinavian journal of work, environment & health.

[240]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[241]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[242]  M. Brin,et al.  Immunohistochemical localization and distribution of torsinA in normal human and rat brain , 2000, Brain Research.

[243]  Min Zhu,et al.  Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.

[244]  Zsuzsanna Dosztányi,et al.  IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..

[245]  Jie Li,et al.  Dopamine and L‐dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[246]  A. Brice,et al.  Alpha-synuclein and Parkinson's disease , 2000, Cellular and Molecular Life Sciences CMLS.

[247]  Hideo Fujiwara,et al.  Accumulation of phosphorylated alpha-synuclein in aging human brain. , 2003, Journal of neuropathology and experimental neurology.

[248]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[249]  P. Lansbury,et al.  Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .

[250]  T. Iwatsubo,et al.  Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. , 2003, Neuroscience Letters.

[251]  V. Uversky,et al.  Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. , 2003, The Journal of biological chemistry.

[252]  V. Buchman,et al.  Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. , 2003, Neuropharmacology.

[253]  T. Iwatsubo,et al.  Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. , 2004, Acta neuropathologica.

[254]  V. Uversky,et al.  Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .

[255]  T. Südhof,et al.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.

[256]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[257]  Clemens R Scherzer,et al.  Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. , 2003, Human molecular genetics.

[258]  Howard J Federoff,et al.  Convergent Pathobiologic Model of Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[259]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[260]  P. Axelsen,et al.  Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .

[261]  V. Uversky,et al.  Methionine oxidation, alpha-synuclein and Parkinson's disease. , 2005, Biochimica et biophysica acta.

[262]  R. Nussbaum,et al.  Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. , 2005, Journal of neurochemistry.

[263]  J. Benovic,et al.  Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases* , 2000, The Journal of Biological Chemistry.

[264]  P. Ballard,et al.  Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983, The New England journal of medicine.

[265]  Hitoshi Takahashi,et al.  NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease , 1997, Neuroscience Letters.

[266]  D. Allan Butterfield,et al.  Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins , 2001, Mechanisms of Ageing and Development.

[267]  M. E. Clark,et al.  Living with water stress: evolution of osmolyte systems. , 1982, Science.

[268]  M. Brin,et al.  TorsinA accumulation in Lewy bodies in sporadic Parkinson’s disease , 2000, Brain Research.

[269]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[270]  V. Uversky,et al.  Polycation‐induced oligomerization and accelerated fibrillation of human α‐synuclein in vitro , 2003 .

[271]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[272]  J. Jeng,et al.  Environmental risk factors and Parkinson's disease , 1997, Neurology.

[273]  V. Uversky,et al.  Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. , 2002, FEBS letters.

[274]  V. Uversky,et al.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.

[275]  J. Ridet,et al.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[276]  J. Trojanowski,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[277]  M. Farrer,et al.  Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .

[278]  Seung-Jae Lee,et al.  Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.

[279]  R. Jakes,et al.  Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.

[280]  A Keith Dunker,et al.  Combining prediction, computation and experiment for the characterization of protein disorder. , 2004, Current opinion in structural biology.

[281]  V. Uversky,et al.  The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. , 2002, The Journal of biological chemistry.

[282]  Vladimir N. Uversky,et al.  Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration , 2004, Cell and Tissue Research.

[283]  P. S. St George-Hyslop,et al.  alpha-Synuclein membrane interactions and lipid specificity. , 2000, The Journal of biological chemistry.

[284]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[285]  E. Stadtman,et al.  Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. , 1993, Annual review of biochemistry.

[286]  A. Minton,et al.  Effect of a concentrated "inert" macromolecular cosolute on the stability of a globular protein with respect to denaturation by heat and by chaotropes: a statistical-thermodynamic model. , 2000, Biophysical journal.

[287]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[288]  Susan E Daniel,et al.  Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain , 2000, Neuroscience Letters.

[289]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[290]  D. Higgins,et al.  In Vivo Labeling of Mitochondrial Complex I (NADH:UbiquinoneOxidoreductase) in Rat Brain Using [3H]Dihydrorotenone , 2000, Journal of neurochemistry.

[291]  V. Uversky,et al.  Agrin binds α-synuclein and modulates α-synuclein fibrillation , 2005 .

[292]  Daniel Otzen,et al.  p25α Stimulates α-Synuclein Aggregation and Is Co-localized with Aggregated α-Synuclein in α-Synucleinopathies* , 2005, Journal of Biological Chemistry.

[293]  Patrick R Hof,et al.  Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain , 2001, Brain Research.

[294]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[295]  P. Caroni,et al.  Neuropathology in mice expressing human alpha-synuclein. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[296]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[297]  Zeger Debyser,et al.  The aggregation of alpha‐synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[298]  Kiowa S. Bower,et al.  Accelerated alpha-synuclein fibrillation in crowded milieu. , 2002, FEBS letters.

[299]  T. Iwatsubo,et al.  Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy , 2004, Acta Neuropathologica.

[300]  P. Fraser,et al.  Review: modulating factors in amyloid-beta fibril formation. , 2000, Journal of structural biology.

[301]  C. C. Lin,et al.  Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. , 2000, Anticancer research.

[302]  Matthew P Frosch,et al.  The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.

[303]  S. Murayama,et al.  Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.

[304]  P. Fraser,et al.  alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. , 2004, European journal of biochemistry.

[305]  R. Uitti,et al.  Parkinsonism induced by solvent abuse , 1994, Annals of neurology.

[306]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[307]  C. Griesinger,et al.  Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. , 2006, Journal of the American Chemical Society.

[308]  K. Arima,et al.  Tubulin seeds alpha-synuclein fibril formation. , 2002, The Journal of biological chemistry.

[309]  M. Frasier,et al.  Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.

[310]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[311]  P. Tompa Intrinsically unstructured proteins. , 2002, Trends in biochemical sciences.

[312]  Philippe Hantraye,et al.  MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.

[313]  N. Voelcker,et al.  Calcium(II) selectively induces α‐synuclein annular oligomers via interaction with the C‐terminal domain , 2004, Protein science : a publication of the Protein Society.

[314]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[315]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[316]  J. Trojanowski,et al.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.

[317]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[318]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[319]  Hui-Bie F. Xu,et al.  Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. , 2001, Pharmacological research.

[320]  Gary J. Pielak,et al.  Solvent‐induced collapse of α‐synuclein and acid‐denatured cytochrome c , 2001 .

[321]  C. Lavedan The synuclein family. , 1998, Genome research.

[322]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[323]  P. Fraser,et al.  Review: Modulating Factors in Amyloid-β Fibril Formation , 2000 .

[324]  Colin L. Masters,et al.  α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores , 1999, Neuroscience Letters.

[325]  M. Hallett,et al.  The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II , 2007, Journal of neuropathology and experimental neurology.

[326]  K. Arima,et al.  Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies , 1998, Brain Research.

[327]  Shubo Han,et al.  The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.

[328]  D. Eliezer,et al.  Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein* , 2001, The Journal of Biological Chemistry.

[329]  R A Crowther,et al.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.

[330]  M. Goedert,et al.  The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. , 2000, Annals of the New York Academy of Sciences.

[331]  Kiowa S. Bower,et al.  Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. , 2002, Neurotoxicology.

[332]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[333]  C. Tanner,et al.  Epidemiology of Parkinson's disease and akinetic syndromes , 2000, Current opinion in neurology.

[334]  J Kim,et al.  Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. , 1997, Archives of biochemistry and biophysics.

[335]  M. Hallett,et al.  The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I , 2007, Journal of neuropathology and experimental neurology.

[336]  Min Zhu,et al.  The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. , 2004, The Journal of biological chemistry.

[337]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[338]  J. Valentine,et al.  Crowding and hydration effects on protein conformation: a study with sol-gel encapsulated proteins. , 2001, Journal of molecular biology.

[339]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[340]  R. Nussbaum,et al.  Fatty acid incorporation is decreased in astrocytes cultured from α‐synuclein gene‐ablated mice , 2005 .

[341]  S. Lindquist,et al.  Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. , 2003, Science.

[342]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[343]  S. Paik,et al.  Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. , 2000, Archives of biochemistry and biophysics.

[344]  V. Uversky,et al.  Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. , 2003, FEBS letters.

[345]  Zheng Rong Yang,et al.  RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins , 2005, Bioinform..

[346]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[347]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[348]  V. Uversky,et al.  Nuclear localization of alpha-synuclein and its interaction with histones. , 2003, Biochemistry.

[349]  A. Minton,et al.  The Influence of Macromolecular Crowding and Macromolecular Confinement on Biochemical Reactions in Physiological Media* , 2001, The Journal of Biological Chemistry.

[350]  V. Uversky,et al.  Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. , 2006, Biochemistry.

[351]  H. Vorum,et al.  Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. , 2001, The Journal of biological chemistry.

[352]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[353]  J. Valentine,et al.  Molecular confinement influences protein structure and enhances thermal protein stability , 2001, Protein science : a publication of the Protein Society.

[354]  P. Lansbury Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[355]  Ralf Langen,et al.  Structure of membrane-bound α-synuclein studied by site-directed spin labeling , 2004 .

[356]  Nutan Sharma,et al.  TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.

[357]  Min Zhu,et al.  Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. , 2006, Biochemistry.

[358]  D. Neill,et al.  Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments , 1998, FEBS letters.

[359]  H. Morris Genetics of Parkinson's disease , 2005, Annals of medicine.

[360]  Hitoshi Takahashi,et al.  α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.

[361]  Jing Zhang,et al.  Identification of Novel Proteins Associated with Both α-Synuclein and DJ-1*S , 2007, Molecular & Cellular Proteomics.

[362]  V. Uversky Natively unfolded proteins: A point where biology waits for physics , 2002, Protein science : a publication of the Protein Society.

[363]  J. Culvenor,et al.  α‐Synuclein Immunoisolation of Glial Inclusions from Multiple System Atrophy Brain Tissue Reveals Multiprotein Components , 1999, Journal of neurochemistry.

[364]  K. Arima,et al.  Tubulin Seeds α-Synuclein Fibril Formation* , 2002, The Journal of Biological Chemistry.

[365]  J. Gorell,et al.  Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.

[366]  Obradovic,et al.  Predicting Protein Disorder for N-, C-, and Internal Regions. , 1999, Genome informatics. Workshop on Genome Informatics.

[367]  A. Doig,et al.  A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. , 2006, Biochemistry.

[368]  P. Jensen,et al.  Pathogenic effects of α-synuclein aggregation , 2005 .

[369]  P. Lansbury,et al.  Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? , 2002, Biochemistry.

[370]  C. Tanner,et al.  The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.

[371]  Ralf Langen,et al.  Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[372]  R. G. Lee,et al.  Parkinson's disease , 1993, Neurology.

[373]  R A Crowther,et al.  Synthetic filaments assembled from C-terminally truncated alpha-synuclein. , 1998, FEBS letters.

[374]  A. Seidler,et al.  Possible environmental, occupational, and other etiologic factors for Parkinson's disease , 1996, Neurology.